Procept BioRobotics Corp(PRCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:24 PM ET (Korea 10/30 05:24)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.95 | Insider Own | 4.63% | Shs Outstand | 57.3M | Perf Week | 1.35% |
| Market Cap | 1.16B | Forward P/E | - | EPS next Y | 31.13% | Insider Trans | 0.83% | Shs Float | 54.6M | Perf Month | 11.42% |
| Enterprise Value | 1.01B | PEG | - | EPS next Q | -0.39 | Inst Own | 95.36% | Short Float | 13.73% | Perf Quarter | 9.02% |
| Income | -0.11B | P/S | 3.45 | EPS this Y | 2.77% | Inst Trans | -5.78% | Short Ratio | 5.54 | Perf Half Y | -15.56% |
| Sales | 0.34B | P/B | 3.42 | EPS next 5Y | 21.44% | ROA | -22.12% | Short Interest | 7.50M | Perf YTD | -35.47% |
| Book/sh | 5.94 | P/C | 5.1 | EPS past 3/5Y | 4.3% -7.02% | ROE | -30.24% | 52W High | -46.73% ($38.11) | Perf Year | -43.5% |
| Cash/sh | 3.98 | P/FCF | - | Sales past 3/5Y | 60.14% 109.04% | ROIC | -26.44% | 52W Low | 21.81% ($16.67) | Perf 3Y | -22.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -25.05% | Gross Margin | 63.74% | Volatility(W/M) | 4.13% 5.47% | Perf 5Y | -52.49% |
| Dividend TTM | - | EV/Sales | 3 | Sales Y/Y TTM | 22.69% | Oper. Margin | -33.86% | ATR (14) | 0.98 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.34 | EPS Q/Q | -33.31% | Profit Margin | -32.54% | RSI (14) | 58.99 | Recom | 2.47 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.54 | Sales Q/Q | 19.34% | SMA20 | 8.53% ($18.7) | Beta | 0.89 | Target Price | $22.25 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/11/4 | SMA50 | 4.47% ($19.43) | Rel Volume | 0.52 | Prev Close | $20.2 |
| Employees | 888 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | -1.75% 1.86% | SMA200 | -13.18% ($23.38) | Avg Volume(3M) | 1.35M | Price | $20.3 |
| IPO | 2021/9/15 | Option/Short | Yes/Yes | Trades | 7089 | Volume | 704,592 | Change | 0.5% |
🤖 This is a US medical device company that develops and sells robotic systems for urological surgery. It provides robotic-based surgical systems and disposable consumables used to treat urological conditions such as benign prostatic hyperplasia, operating on a model that combines system installation with procedure-related consumables. The company is positioned as a growth-stage medical device business specializing in urological surgical robotics.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
Next earnings report: November 4
5 days to go.
PRCT has a sound balance sheet but weak earning power
Of every $100 in sales, $33.86 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $345. Peers typically go for $345. Compared with its own 2-year average, it is 71% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -52.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 95.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #38 of 142 in the industry
Based on market cap of $1B.
BVS#37 Bioventus Inc $1B PER 19.2 PRCT#38 Procept BioRobotics Corp $1B PER - 
AORT#39 Artivion Inc $1B PER - 
LMRI#40 Lumexa Imaging Holdings Inc $1B PER - 
IRMD#41 Iradimed Corp $1B PER 47.9 
FAQ
What kind of company is PRCT?
PRCT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PRCT?
The market cap of PRCT is approximately $1.2B, ranking 2,478 within its sector.
What is the 52-week high and low for PRCT?
PRCT has recorded a 52-week high of $38.11 and a low of $16.67.
